ARVO to host demonstration of results from two clinical trials on neovascular AMD Unique session at the 2012 ARVO Annual Meeting ARVO is normally very happy to host a presentation of the one-year results from the U http://www.suhagrarx.com/ .K.’s Inhibition of VEGF in Age-related Choroidal Neovascularisation research and the two-year outcomes of the Evaluation of Age-related Macular Degeneration Treatments Trials trial. Both of these multicenter randomized medical trials, sponsored by the National Institute of Health Research in the United Kingdom and the National Attention Institute, respectively, measure the relative efficacy and security of Lucentis and Avastin in the management of neovascular age-related macular degeneration .
The PACE trial is designed to provide definitive clinical data for regulatory authorization of ponatinib in this establishing. Ponatinib has been granted orphan drug position in both the USA and European countries for the treatment of CML and Ph+ ALL. Berger, M.D., chairman and ceo. ‘With the strong scientific evidence observed to time of hematologic, cytogenetic and molecular anti-leukemia activity of ponatinib in seriously pretreated individuals with CML, including those sufferers with the T315I mutation for whom no current treatments are available, we are highly optimistic about the likelihood of success for ponatinib in this registration trial.